HPV and cervical cancer epidemiology - Current status of HPV vaccination in India

Sharmila Chatterjee, Amit Chattopadhyay, Luna Samanta, Pinaki Panigrahi

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Cervical cancer (CaCx) is the second most fatal cancer contributing to 14% of cancers in Indian females, which account for 25.4% and 26.5% of the global burden of CaCx prevalence and mortality, respectively. Persistent infection with high-risk human papilloma virus (HPV- strains 16 and 18) is the most important risk factor for precursors of invasive CaCx. Comprehensive prevention strategies for CaCx should include screening and HPV vaccination. Three screening modalities for CaCx are cytology, visual inspection with acetic acid, and HPV testing. There is no Indian national policy on CaCx prevention, and screening of asymptomatic females against CaCx is practically non-existent. HPV vaccines can make a major breakthrough in the control of CaCx in India which has high disease load and no organized screening program. Despite the Indian Government's effort to introduce HPV vaccination in the National Immunization Program and bring down vaccine cost, challenges to implementing vaccination in India are strong such as: inadequate epidemiological evidence for disease prioritization, duration of vaccine use, parental attitudes, and vaccine acceptance. This paper reviews the current epidemiology of CaCx and HPV in India, and the current status of HPV vaccination in the country. This article stresses the need for more research in the Indian context, to evaluate interventions for CaCx and assess their applicability, success, scalability and sustainability within the constraints of the Indian health care system.

Original languageEnglish (US)
Pages (from-to)3663-3673
Number of pages11
JournalAsian Pacific Journal of Cancer Prevention
Volume17
Issue number8
StatePublished - Jan 1 2016

Fingerprint

Uterine Cervical Neoplasms
India
Vaccination
Epidemiology
Vaccines
Papillomaviridae
Papillomavirus Vaccines
Human papillomavirus 18
Immunization Programs
Human papillomavirus 16
Acetic Acid
Cell Biology
Neoplasms
Delivery of Health Care
Costs and Cost Analysis
Mortality
Infection
Research

Keywords

  • Cervical cancer
  • India-prevalence
  • Papilloma virus vaccines
  • Risk factors

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

Chatterjee, S., Chattopadhyay, A., Samanta, L., & Panigrahi, P. (2016). HPV and cervical cancer epidemiology - Current status of HPV vaccination in India. Asian Pacific Journal of Cancer Prevention, 17(8), 3663-3673.

HPV and cervical cancer epidemiology - Current status of HPV vaccination in India. / Chatterjee, Sharmila; Chattopadhyay, Amit; Samanta, Luna; Panigrahi, Pinaki.

In: Asian Pacific Journal of Cancer Prevention, Vol. 17, No. 8, 01.01.2016, p. 3663-3673.

Research output: Contribution to journalReview article

Chatterjee, S, Chattopadhyay, A, Samanta, L & Panigrahi, P 2016, 'HPV and cervical cancer epidemiology - Current status of HPV vaccination in India', Asian Pacific Journal of Cancer Prevention, vol. 17, no. 8, pp. 3663-3673.
Chatterjee S, Chattopadhyay A, Samanta L, Panigrahi P. HPV and cervical cancer epidemiology - Current status of HPV vaccination in India. Asian Pacific Journal of Cancer Prevention. 2016 Jan 1;17(8):3663-3673.
Chatterjee, Sharmila ; Chattopadhyay, Amit ; Samanta, Luna ; Panigrahi, Pinaki. / HPV and cervical cancer epidemiology - Current status of HPV vaccination in India. In: Asian Pacific Journal of Cancer Prevention. 2016 ; Vol. 17, No. 8. pp. 3663-3673.
@article{8dbc206061874ff5ae2f570a6bd629c6,
title = "HPV and cervical cancer epidemiology - Current status of HPV vaccination in India",
abstract = "Cervical cancer (CaCx) is the second most fatal cancer contributing to 14{\%} of cancers in Indian females, which account for 25.4{\%} and 26.5{\%} of the global burden of CaCx prevalence and mortality, respectively. Persistent infection with high-risk human papilloma virus (HPV- strains 16 and 18) is the most important risk factor for precursors of invasive CaCx. Comprehensive prevention strategies for CaCx should include screening and HPV vaccination. Three screening modalities for CaCx are cytology, visual inspection with acetic acid, and HPV testing. There is no Indian national policy on CaCx prevention, and screening of asymptomatic females against CaCx is practically non-existent. HPV vaccines can make a major breakthrough in the control of CaCx in India which has high disease load and no organized screening program. Despite the Indian Government's effort to introduce HPV vaccination in the National Immunization Program and bring down vaccine cost, challenges to implementing vaccination in India are strong such as: inadequate epidemiological evidence for disease prioritization, duration of vaccine use, parental attitudes, and vaccine acceptance. This paper reviews the current epidemiology of CaCx and HPV in India, and the current status of HPV vaccination in the country. This article stresses the need for more research in the Indian context, to evaluate interventions for CaCx and assess their applicability, success, scalability and sustainability within the constraints of the Indian health care system.",
keywords = "Cervical cancer, India-prevalence, Papilloma virus vaccines, Risk factors",
author = "Sharmila Chatterjee and Amit Chattopadhyay and Luna Samanta and Pinaki Panigrahi",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "17",
pages = "3663--3673",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "8",

}

TY - JOUR

T1 - HPV and cervical cancer epidemiology - Current status of HPV vaccination in India

AU - Chatterjee, Sharmila

AU - Chattopadhyay, Amit

AU - Samanta, Luna

AU - Panigrahi, Pinaki

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cervical cancer (CaCx) is the second most fatal cancer contributing to 14% of cancers in Indian females, which account for 25.4% and 26.5% of the global burden of CaCx prevalence and mortality, respectively. Persistent infection with high-risk human papilloma virus (HPV- strains 16 and 18) is the most important risk factor for precursors of invasive CaCx. Comprehensive prevention strategies for CaCx should include screening and HPV vaccination. Three screening modalities for CaCx are cytology, visual inspection with acetic acid, and HPV testing. There is no Indian national policy on CaCx prevention, and screening of asymptomatic females against CaCx is practically non-existent. HPV vaccines can make a major breakthrough in the control of CaCx in India which has high disease load and no organized screening program. Despite the Indian Government's effort to introduce HPV vaccination in the National Immunization Program and bring down vaccine cost, challenges to implementing vaccination in India are strong such as: inadequate epidemiological evidence for disease prioritization, duration of vaccine use, parental attitudes, and vaccine acceptance. This paper reviews the current epidemiology of CaCx and HPV in India, and the current status of HPV vaccination in the country. This article stresses the need for more research in the Indian context, to evaluate interventions for CaCx and assess their applicability, success, scalability and sustainability within the constraints of the Indian health care system.

AB - Cervical cancer (CaCx) is the second most fatal cancer contributing to 14% of cancers in Indian females, which account for 25.4% and 26.5% of the global burden of CaCx prevalence and mortality, respectively. Persistent infection with high-risk human papilloma virus (HPV- strains 16 and 18) is the most important risk factor for precursors of invasive CaCx. Comprehensive prevention strategies for CaCx should include screening and HPV vaccination. Three screening modalities for CaCx are cytology, visual inspection with acetic acid, and HPV testing. There is no Indian national policy on CaCx prevention, and screening of asymptomatic females against CaCx is practically non-existent. HPV vaccines can make a major breakthrough in the control of CaCx in India which has high disease load and no organized screening program. Despite the Indian Government's effort to introduce HPV vaccination in the National Immunization Program and bring down vaccine cost, challenges to implementing vaccination in India are strong such as: inadequate epidemiological evidence for disease prioritization, duration of vaccine use, parental attitudes, and vaccine acceptance. This paper reviews the current epidemiology of CaCx and HPV in India, and the current status of HPV vaccination in the country. This article stresses the need for more research in the Indian context, to evaluate interventions for CaCx and assess their applicability, success, scalability and sustainability within the constraints of the Indian health care system.

KW - Cervical cancer

KW - India-prevalence

KW - Papilloma virus vaccines

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84988422009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988422009&partnerID=8YFLogxK

M3 - Review article

C2 - 27644600

AN - SCOPUS:84988422009

VL - 17

SP - 3663

EP - 3673

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 8

ER -